Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Net Margin (2019 - 2025)

Historic Net Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 1162.38%.

  • Beam Therapeutics' Net Margin fell 4849200.0% to 1162.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 744.41%, marking a year-over-year decrease of 7033400.0%. This contributed to the annual value of 593.13% for FY2024, which is 5580400.0% down from last year.
  • Per Beam Therapeutics' latest filing, its Net Margin stood at 1162.38% for Q3 2025, which was down 4849200.0% from 1208.26% recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Net Margin registered a high of 45.16% during Q4 2023, and its lowest value of 3359333.33% during Q1 2021.
  • Its 5-year average for Net Margin is 244442.45%, with a median of 693.56% in 2022.
  • In the last 5 years, Beam Therapeutics' Net Margin tumbled by 2000000000bps in 2021 and then surged by 2000000000bps in 2022.
  • Beam Therapeutics' Net Margin (Quarter) stood at 126.71% in 2021, then plummeted by -51bps to 191.39% in 2022, then surged by 124bps to 45.16% in 2023, then crashed by -765bps to 300.51% in 2024, then tumbled by -287bps to 1162.38% in 2025.
  • Its Net Margin was 1162.38% in Q3 2025, compared to 1208.26% in Q2 2025 and 1462.78% in Q1 2025.